Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Related Keywords

Marcia Brose , ,Treatment Approaches ,Sequencing Strategies ,Differentiated Thyroid Cancer ,With Frontline Lenvatinib ,Thyroid Cancer ,Dtc Cancer ,Dtc ,Rr Dtc ,Radioiodine Refractory ,Radioiodine Refractory Dtc ,Lenvatinib ,First Line Therapy ,First Line Treatment ,Dose Reduction ,Dose Adjustment ,Lenvatinib Dosing ,Adverse Events ,Drug Adverse Event ,Hypertension Management ,